Reclassifying neurodegenerative diseases

An Author Correction to this article was published on 17 September 2020

This article has been updated

Neuropathologies can be classified, on the basis of post-mortem histopathology and by using machine learning, into six transdiagnostic clusters associated with clinical phenotypes.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Clusters of neurodegenerative diseases defined by pathological features.

Change history

  • 17 September 2020

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  1. 1.

    Soria Lopez, J. A., Gonzalez, H. M. & Leger, G. C. Handb. Clin. Neurol. 167, 231–255 (2019).

    Article  Google Scholar 

  2. 2.

    Butler, P. M. & Chiong, W. Handb. Clin. Neurol. 163, 391–410 (2019).

    Article  Google Scholar 

  3. 3.

    Kovacs, G. G. Handb. Clin. Neurol. 145, 355–368 (2017).

    Article  Google Scholar 

  4. 4.

    Alafuzoff, I. & Hartikainen, P. Handb. Clin. Neurol. 145, 339–353 (2017).

    Article  Google Scholar 

  5. 5.

    Peng, C., Trojanowski, J. Q. & Lee, V. M. Nat. Rev. Neurol. 16, 199–212 (2020).

    CAS  Article  Google Scholar 

  6. 6.

    Elahi, F. M. & Miller, B. L. Nat. Rev. Neurol. 13, 457–476 (2017).

    Article  Google Scholar 

  7. 7.

    Karanth, S. et al. JAMA Neurol. (2020).

  8. 8.

    Cornblath, E. J. et al. Nat. Biomed. Eng. (2020).

  9. 9.

    Toledo, J. B. et al. Alzheimers Dement. 10, 477–484 (2014).

    Article  Google Scholar 

  10. 10.

    Ransohoff, R. M. Science 353, 777–783 (2016).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Pablo Villoslada.

Ethics declarations

Competing interests

P.V. owns stocks and has received consultancy fees from Accure Therapeutics, Health Engineering, QMENTA, Attune Neurosciences, CLight, NeuroPrex and Spiral Therapeutics. These companies are not associated with this work. J.C.M. has received consultancy fees from Biogen and is on their Speaker Bureau, and has received research support from AbbVie, Biogen, Esai, Eli Lilly and Company, and Novartis. R.B.-Y. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Villoslada, P., Baeza-Yates, R. & Masdeu, J.C. Reclassifying neurodegenerative diseases. Nat Biomed Eng 4, 759–760 (2020).

Download citation


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing